This application is a for 5-year renewal of the program project, Healthy Aging and Senile Dementia (HASD), now in its 14th year. In this renewal there is a continued focus on the clinical, psychometric, and neuropathologic correlates of DAT in comparison with healthy aging. Five interactive and supportive Cores are proposed: Core A: Clinical recruits, enrolls, and clinically assesses subjects annually to supply all projects; Core B: Psychometrics provides longitudinal cognitive assessments of subjects; Core C: Neuropathology performs postmortem examinations for clinicopathological correlation for all studies and provides appropriate tissue and data to Projects 2 and 4; Core D: Biostatistics oversees data management and provides statistical input to all Cores and projects; and Core E: Administration provides administrative support to all components and assures progress in accomplishing program project goals. Three current projects continue. Project 1 (""""""""Intellect and Alzheimer changes in the very old"""""""") examines clinical, psychometric, and neuropathologic differences and overlap in nondemented and demented subjects greater than or equal to 85. Project 2 (""""""""Mapping of neuropathology in healthy aging and dementia"""""""") studies preclinical stages of Alzheimer's disease (AD) in comparison with healthy brain aging and mild DAT. Project 3 (""""""""Frontal control systems and memory in aging and DAT"""""""") explores the contributions of medial temporal and frontal systems to cognitive performance in aging and DAT. A new study, Project 4 (""""""""Imaging neuronal loss with MRI/MRS in DAT and controls"""""""") evaluates the ability of sensitive neuroimaging measures to discriminate aging and very mild DAT. Together, these projects and their supporting cores will define very mild DAT in comparison with healthy brain aging and address the critical problem of whether aging and AD are continuous or discrete processes.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003991-19
Application #
6509472
Study Section
Special Emphasis Panel (ZAG1-DAG-9 (J3))
Program Officer
Buckholtz, Neil
Project Start
1984-01-01
Project End
2003-12-31
Budget Start
2002-01-01
Budget End
2002-12-31
Support Year
19
Fiscal Year
2002
Total Cost
$1,915,269
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Rao, Shuquan; Ghani, Mahdi; Guo, Zhiyun et al. (2018) An APOE-independent cis-eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. Neurobiol Aging 66:178.e1-178.e8
Roe, Catherine M; Babulal, Ganesh M; Mishra, Shruti et al. (2018) Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. J Alzheimers Dis 61:509-513
Peloso, Gina M; van der Lee, Sven J; International Genomics of Alzheimer's Project (IGAP) et al. (2018) Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimers Dement (Amst) 10:595-598
Laurido-Soto, Osvaldo; Brier, Matthew R; Simon, Laura E et al. (2018) Patient characteristics and outcome associations in AMPA receptor encephalitis. J Neurol :
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98:861-864
Armstrong, Richard A; McKee, Ann C; Stein, Thor D et al. (2018) Cortical degeneration in chronic traumatic encephalopathy and Alzheimer's disease neuropathologic change. Neurol Sci :
Millar, Peter R; Balota, David A; Bishara, Anthony J et al. (2018) Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease. Mem Cognit 46:1058-1075
Deming, Yuetiva; Li, Zeran; Benitez, Bruno A et al. (2018) Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? Expert Opin Ther Targets 22:587-598
Vlassenko, Andrei G; Gordon, Brian A; Goyal, Manu S et al. (2018) Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiol Aging 67:95-98
Musiek, Erik S; Bhimasani, Meghana; Zangrilli, Margaret A et al. (2018) Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol 75:582-590

Showing the most recent 10 out of 911 publications